5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients

Nature Communications

Volumn 7, Issue , 2016, Pages

  Johnson, Kevin C ^a   Houseman, E Andres ^b   King, Jessica E ^a   Von Herrmann, Katharine M ^a   Fadul, Camilo E ^c   Christensen, Brock C ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; BISULFITE; DNA; TRANSCRIPTION FACTOR; 5-HYDROXYMETHYLCYTOSINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ALGORITHM; ARRAY; CELLS AND CELL COMPONENTS; DNA; GENE EXPRESSION; GENOMICS; METHYLATION; MOLECULAR ANALYSIS; NERVOUS SYSTEM DISORDER; SURVIVAL;

ADULT; AGED; ARTICLE; BINDING SITE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; ENHANCER REGION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; OXIDATION; PREFRONTAL CORTEX; PROMOTER REGION; STEM CELL; ANALOGS AND DERIVATIVES; BRAIN TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

5-METHYLCYTOSINE; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; PREFRONTAL CORTEX; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84998554798     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13177     Document Type: Article

References (63)

1. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro. Oncol. 15(Suppl 2): ii1-56 (2013).
2. Ostrom, Q. T. et al. The epidemiology of glioma in adults: a 'state of the science' review. Neuro. Oncol. 16, 896-913 (2014).
3. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
4. Eckel-Passow, J. E. et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499-2508 (2015).
5. Cancer Genome Atlas Research N et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
6. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
7. Christensen, B. C. et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl Cancer. Inst. 103, 143-153 (2011).
8. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
9. Zheng, S. et al. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro. Oncol. 13, 280-289 (2011).
10. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 (2016).
11. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
12. Kreth, S., Thon, N. & Kreth, F. W. Epigenetics in human gliomas. Cancer. Lett. 342, 185-192 (2014).
13. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
14. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
15. Bachman, M. et al. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat. Chem. 6, 1049-1055 (2014).
16. Vasanthakumar, A. & Godley, L. A. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. 208, 167-177 (2015).
17. Takai, H. et al. 5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Rep. 9, 48-60 (2014).
18. Booth, M. J. et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336, 934-937 (2012).
19. Field, S. F. et al. Accurate measurement of 5-methylcytosine and 5-hydroxymethylcytosine in human cerebellum DNA by oxidative bisulfite on an array (OxBS-array). PLoS ONE 10, e0118202 (2015).
20. Stewart, S. K. et al. oxBS-450K: a method for analysing hydroxymethylation using 450 K BeadChips. Methods 72, 9-15 (2015).
21. Houseman, E. A., Johnson, K. C. & Christensen, B. C. OxyBS: estimation of 5-methylcytosine and 5-hydroxymethylcytosine from tandem-treated oxidative bisulfite and bisulfite DNA. Bioinformatics 32, 2505-2507 (2016).
22. Uribe-Lewis, S. et al. 5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer. Genome Biol. 16, 69 (2015).
23. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484-492 (2012).
24. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343-348 (2011).
25. Song, C. X. & He, C. Balance of DNA methylation and demethylation in cancer development. Genome Biol. 13, 173 (2012).
26. Ivanov, M. et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 14, R83 (2013).
27. Stroud, H., Feng, S., Morey Kinney, S., Pradhan, S. & Jacobsen, S. E. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol. 12, R54 (2011).
28. Lunnon, K. et al. Variation in 5-hydroxymethylcytosine across human cortex and cerebellum. Genome Biol. 17, 27 (2016).
29. Wen, L. & Tang, F. Genomic distribution and possible functions of DNA hydroxymethylation in the brain. Genomics 104, 341-346 (2014).
30. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
31. Neri, F. et al. Genome-wide analysis identifies a functional association of Tet1 and polycomb repressive complex 2 in mouse embryonic stem cells. Genome Biol. 14, R91 (2013).
32. Yu, M. et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 149, 1368-1380 (2012).
33. Sheffield, N. C. & Bock, C. LOLA: enrichment analysis for genomic region sets and regulatory elements in R and bioconductor. Bioinformatics 32, 587-589 (2016).
34. Gustems, M. et al. c-Jun/c-Fos heterodimers regulate cellular genes via a newly identified class of methylated DNA sequence motifs. Nucleic Acids Res. 42, 3059-3072 (2014).
35. Schnetz, M. P. et al. CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression. PLoS Genet. 6, e1001023 (2010).
36. Ryan, M. et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 44, D1018-D1022 (2016).
37. Orr, B. A., Haffner, M. C., Nelson, W. G., Yegnasubramanian, S. & Eberhart, C. G. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS ONE 7, e41036 (2012).
38. Langevin, S. M. et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics 7, 291-299 (2012).
39. Koestler, D. C. et al. Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. Cancer Epidemiol. Biomarkers Prev. 21, 1293-1302 (2012).
40. Marsit, C. J. et al. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J. Clin. Oncol. 29, 1133-1139 (2011).
41. Jin, S. G. et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 71, 7360-7365 (2011).
42. Kraus, T. F. et al. Low values of 5-hydroxymethylcytosine (5hmC), the 'sixth base,' are associated with anaplasia in human brain tumors. Int. J. Cancer 131, 1577-1590 (2012).
43. Kraus, T. F. et al. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma. Tumour Biol. 36, 8439-8446 (2015).
44. Muller, T. et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 181, 675-683 (2012).
45. Ahsan, S. et al. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 2, 59 (2014).
46. Ziller, M. J., Hansen, K. D., Meissner, A. & Aryee, M. J. Coverage recommendations for methylation analysis by whole-genome bisulfite sequencing. Nat. Methods 12, 230-232 (2015).
47. Matsubara, K. et al. Exploration of hydroxymethylation in Kagami-Ogata syndrome caused by hypermethylation of imprinting control regions. Clin. Epigenetics 7, 90 (2015).
48. Kafer, G. R. et al. 5-Hydroxymethylcytosine marks sites of DNA damage and promotes genome stability. Cell Rep. 14, 1283-1292 (2016).
49. Jin, S. G., Wu, X., Li, A. X. & Pfeifer, G. P. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 39, 5015-5024 (2011).
50. Rampal, R. et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 9, 1841-1855 (2014).
51. Friedmann-Morvinski, D. et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080-1084 (2012).
52. Hon, G. C. et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell 56, 286-297 (2014).
53. Taylor, S. E. et al. Stable 5-Hydroxymethylcytosine (5hmC) acquisition marks gene activation during chondrogenic differentiation. J. Bone Miner. Res. 31, 524-534 (2016).
54. Jackson, M., Hassiotou, F. & Nowak, A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis 36, 177-185 (2015).
55. Moen, E. L., Stark, A. L., Zhang, W., Dolan, M. E. & Godley, L. A. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol. Cancer Ther. 13, 1334-1344 (2014).
56. Aryee, M. J. et al. Minfi: a flexible and comprehensive bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363-1369 (2014).
57. Chen, Y. A. et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8, 203-209 (2013).
58. Dedeurwaerder, S. et al. Evaluation of the infinium methylation 450 K technology. Epigenomics 3, 771-784 (2011).
59. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495-501 (2010).
60. Houseman, E. A., Molitor, J. & Marsit, C. J. Reference-free cell mixture adjustments in analysis of DNA methylation data. Bioinformatics 30, 1431-1439 (2014).
61. Houseman, E. A. et al. Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. BMC Bioinform. 17, 259 (2016).
62. Akalin, A., Franke, V., Vlahovicek, K., Mason, C. E. & Schubeler, D. Genomation: a toolkit to summarize, annotate and visualize genomic intervals. Bioinformatics 31, 1127-1129 (2015).
63. Suva, M. L. et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157, 580-594 (2014).